Abstract:Iron is essential for all organisms and cells. Diseases of iron imbalance affect billions of patients, including those with iron overload and other forms of iron toxicity. Excess iron load is an adverse prognostic factor for all diseases and can cause serious organ damage and fatalities following chronic red blood cell transfusions in patients of many conditions, including hemoglobinopathies, myelodyspasia, and hematopoietic stem cell transplantation. Similar toxicity of excess body iron load but at a slower rate of disease progression is found in idiopathic haemochromatosis patients. Excess iron deposition in different regions of the brain with suspected toxicity has been identified by MRI T2* and similar methods in many neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Based on its role as the major biological catalyst of free radical reactions and the Fenton reaction, iron has also been implicated in all diseases associated with free radical pathology and tissue damage. Furthermore, the recent discovery of ferroptosis, which is a cell death program based on free radical generation by iron and cell membrane lipid oxidation, sparked thousands of investigations and the association of iron with cardiac, kidney, liver, and many other diseases, including cancer and infections. The toxicity implications of iron in a labile, non-protein bound form and its complexes with dietary molecules such as vitamin C and drugs such as doxorubicin and other xenobiotic molecules in relation to carcinogenesis and other forms of toxicity are also discussed. In each case and form of iron toxicity, the mechanistic insights, diagnostic criteria, and molecular interactions are essential for the design of new and effective therapeutic interventions and of future targeted therapeutic strategies. In particular, this approach has been successful for the treatment of most iron loading conditions and especially for the transition of thalassemia from a fatal to a chronic disease due to new therapeutic protocols resulting in the complete elimination of iron overload and of iron toxicity.

Management of iron overload: lessons from transfusion-dependent hemoglobinopathies

Management of iron overload in hemoglobinopathies: what is the appropriate target iron level?

Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series

Iron overload: the Achilles heel of β- thalassemia

Anemia and iron overload as prognostic markers of outcomes in β-thalassemia

Diagnosis and Management of Genetic Iron Overload Disorders

Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate

A Review of Iron Overload in Beta-Thalassemia Major, and a Discussion on Alternative Potent Iron Chelation Targets

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia

Clinical Challenges with Iron Chelation in Beta Thalassemia

The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review

How I manage iron overload in the hemopoietic cell transplantation setting

Iron Load Toxicity in Medicine: From Molecular and Cellular Aspects to Clinical Implications

Revisiting iron overload status and change thresholds as predictors of mortality in transfusion-dependent β-thalassemia: a 10-year cohort study

Iron metabolism and iron disorders revisited in the hepcidin era

[Heavy metal! A case of severe iron overload and supraventricular arrhythmias in a thalassemia major patient]

How I treat iron overload in adult myelodysplastic syndrome

Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs

Dysregulation of Iron Metabolism in Cardiovascular Diseases: from Iron Deficiency to Iron Overload

Thalassemia major between liver and heart: Where we are now

Management of the aging beta-thalassemia transfusion-dependent population - The Italian experience